Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P674: Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Szántó1, A. L. Szíjártó2, D. Kata3, I. Földesi3, Z. A. Mezei4, A. Fábián1, A. Bálint1, R. Bor1, K. Farkas1, Á. Milassin1, M. Rutka1, Z. Szepes1, F. Nagy1, T. Bubán5, S. Lovas6, K. Palatka6, T. Molnár1

1University of Szeged, First Department of Medicine, Szeged, Hungary, 2University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, 3University of Szeged, Institute of Laboratory Medicine, Szeged, Hungary, 4University of Debrecen, Department of Laboratory Medicine, Debrecen, Hungary, 5University of Debrecen, Department of Internal Medicine, Debrecen, Hungary, 6University of Szeged, 2nd Department of Internal Medicine, Debrecen, Hungary

P675: The relationship between gender, severity of disease, treatment type, and employment outcome in patients with inflammatory bowel disease in Israel

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Naftali*1,2, A. Ein Dor Abarbanel3, N. Ruhimovich2, A. Bar-Gil Shitrit4, F. Sklerovsky-Benjaminov1,2, H. Shirin1,3, S. Matalon1,3, T. Ziv Baran5, E. Broide1,3

1Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel, 2Meir Hospital, Gastroenterology and Liver disease, Kfar Saba, Israel, 3Assaf Harofeh, The Kamila Gonczarowski Institute for Gastroenterology and Liver Diseases, Zerifin, Israel, 4Shaare Zedek Medical Center, Gastroenterology institute, Jerusalem, Israel, 5Sackler Faculty of Medicine Tel Aviv University, Department of Epidemiology and Preventive Medicine, Tel aviv, Israel

P676: The impact to disease activity, iron and vitamin D deficiency on fatigue in IBD patients

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Atanassova*1, A. Georgieva1, D. Gerova2, M. Todorova2

1Medical University Varna, Clinic of Hepatogastroenterology, St. Marina University Hospital, Varna, Bulgaria, 2Medical University Varna, Department of General Medicine and Clinical Laboratory, Varna, Bulgaria

P677: Effect of late faecal loss of infliximab on treatment response of inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

F. AlborziAvanaki*1, H. Rezvan1, N. Ebrahimi Daryani1, N. Ale Taha1

1Tehran university ofMedical Sciences, Tehran, Iran, Islamic Republic of

P678: Treatment of moderate to severe UC patients with new 5ASA tablets

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Laoun*1, R. Hofmann2

1Tillotts Pharma AG, Medical Affairs, Rheinfelden, Switzerland, 2Tillotts Pharma, Medicines Management, Rheinfelden, Switzerland

P679: Development of a novel auto-injector of subcutaneous CT-P13 infliximab: Phase I randomised, open-label, single-dose trial to compare the pharmacokinetics and safety to pre-filled syringe in healthy subjects

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Schreiber*1, S. Ben-Horin2, B. D. Ye3, R. Westhovens4, D. H. Yoo5, S. J. Lee6, J. H. Suh6, J. H. Byeon6, W. Reinisch7

1University Hospital Schleswig-Holstein, Kiel, Germany, 2Sheba Medical Center, Tel Hashomer, Israel, 3Asan Medical Center, Seoul, South Korea, 4University Hospital KU Leuven, Leuven, Belgium, 5Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 6Celltrion, Inc., Incheon, South Korea, 7Medical University Vienna, Vienna, Austria

P680: Long-term efficacy of ustekinumab with and without concomitant immunosuppressants for Crohn’s disease: results from IM-UNITI long-term extension through 2 years

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Ghosh*1, B. C. Kramer2, C. Gasink2, D. Jacobstein3, O. J. Adedokun3, L-L. Gao3, P. Rutgeerts4, B. E. Sands5

1University of Birmingham, Birmingham, UK, 2Janssen Scientific Affairs, LLC, Horsham, USA, 3Janssen Research and Development, LLC, Spring House, USA, 4University Hospital Gasthuisberg, Leuven, Belgium, 5Icahn School of Medicine at Mount Sinai, New York, USA

P681: Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies

ECCO '19 Copenhagen

Year: 2019
Authors:

B. E. Sands*1, C. Han2, H. Zhang3, J. Johanns3, P. Szapary3, C. Marano3, R. W. Leong4,5, S. Danese6

1Icahn School of Medicine at Mount Sinai, New York, USA, 2Janssen Global Services, LLC, Malvern, USA, 3Janssen Research & Development, LLC, Spring House, USA, 4Concord Hospital, Sydney, Australia, 5Macquarie University Hospital, Sydney, Australia, 6Humanitas Research Hospital, Milan, Italy

P682: GO-CARE: a prospective multi-centre observational study of golimumab effectiveness and quality of life in a real life UC patient population in Italy

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Armuzzi1, A. Gasbarrini2, S. Marchi3, S. Saibeni4, V. Germano*5, S. Cercone5, F. Bossa7, A. C. Privitera8

1IBD Unit, Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, 2Internal Medicine, Gastroenterology and Liver Unit, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy, 3Division of Gastroenterology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, 4Gastroenterology Unit, RhoHospital, Rho, Italy, 5MSD Italia, Rome, Italy, 7Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Foggia, Italy, 8IBD and Pelvic Floor Unit, Azienda Ospedaliera per l'Emergenza, Ospedale Cannizzaro, Catania, Italy

P683: Higher serum golimumab concentrations are significantly associated with combined clinical-biochemical remission during maintenance therapy: results from the GO-LEVEL study

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Samaan*1, G. Cunningham1, A. G. Tamilarasan1, K. Rawstron2, K. Hawash2, L. Beltran2, I. Koumoutsos1, S. Ray1, J. Mawdsley1, S. Anderson1, J. Sanderson1, Z. Arkir2, P. Irving1

1Guy's & St Thomas' Hospital, Gastroenterology, London, UK, 2Guy's & St Thomas' Hospital, Viapath Laboratories, London, UK

P684: Vaccination strategies for IBD patients

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Sitibondo*1, A. Squeri1, A. Viola1, G. Costantino1, A. Belvedere1, V. Pisana1, F. Costa2, R. Squeri2, W. Fries1

1AOU G. Martino, Department of Clinical and Experimental Medicine, IBD Unit, University of Messina, Messina, Italy, 2AOU G. Martino, Vaccination Centre, Department of Biomedical Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy

P685: Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials

ECCO '19 Copenhagen

Year: 2019
Authors:

M. C. Dubinsky1, B. Bressler2, A. Armuzzi*3, L. Salese4, M. DiBonaventura5, E. Maller4, H. Fan4, D. A. Woodworth4, C. Su4

1Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, USA, 2University of British Columbia, Division of Gastroenterology, Department of Medicine, Vancouver, BC, Canada, 3Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, IBD Unit, Rome, Italy, 4Pfizer Inc., Collegeville, PA, USA, 5Pfizer Inc., New York, NY, USA

P686: Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Kurent*1, U. Koren2, J. Hanzel1, M. Kozelj1, G. Novak1, N. Smrekar1, B. Stabuc1, N. Kecelj3, D. Drobne1

1University Medical Centre Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia, 2University of Ljubljana, Faculty of Pharmacy, Ljubljana, Slovenia, 3University Medical Centre Ljubljana, Department of Dermatology, Ljubljana, Slovenia

P687: Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial

ECCO '19 Copenhagen

Year: 2019
Authors:

B. G. Feagan*1, W. J. Sandborn2, G. D'Haens3, S. Hanauer4, D. C. Wolf5, S. Vermeire6, S. Ghosh7, A. Petersen8, S. Y. Hua8, K. Shan8, J. Liu8

1Robarts Clinical Trials, Western University, London, Canada, 2University of California - San Diego, San Diego, USA, 3Academic Medical Center, Amsterdam, The Netherlands, 4Feinberg School of Medicine, Chicago, USA, 5Atlanta Gastroenterology Associates, Atlanta, USA, 6University of Leuven, Leuven, Belgium, 7University of Calgary, Calgary, Canada, 8Celgene Corporation, Summit, USA

P688: Ustekinumab in resistant Crohn’s disease: 1-year UK IBD tertiary referral centre ‘real-world’ experience

ECCO '19 Copenhagen

Year: 2019
Authors:

S. P. Borg-Bartolo*1, K. Kemp1, R. P. Willert1, A. J. Makin1, S. E. Levison1

1Manchester University NHS Foundation Trust, Department of Gastroenterology, Manchester, UK

P689: The effect of nutritional therapy on bone mineral density and bone metabolism in paediatric Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Lev-Tzion*1, T. Ben-Moshe1, G. Abitbol1, O. Ledder1,2, A. Levine3,4, S. Peleg5,6, P. Millman7, R. Shaoul6,8, H. Shamaly9, A. On10,11, M. Kori2,12, A. Assa13,14, S. Cohen4,15, E. Broide4,16, D. Turner1,2

1Shaare Zedek Medical Center, Jerusalem, Israel, 2The Hebrew University of Jerusalem, Jerusalem, Israel, 3Edith Wolfson Medical Center, Holon, Israel, 4Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, 5Ha'Emek Medical Center, Afula, Israel, 6The Ruth and Bruce Rappaport School of Medicine, Technion - Israel Institute of Technology, Haifa, Israel, 7Hadassah-Hebrew University Medical Center, Jerusalem, Israel, 8Rambam Medical Center, Haifa, Israel, 9French Hospital, Nazareth, Israel, 10Baruch Padeh Medical Center, Poriya, Israel, 11Bar-Ilan University, Galille, Israel, 12Kaplan Medical Center, Rehovot, Israel, 13Schneider Children's Medical Center, Petach Tikva, Israel, 14Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel, 15Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 16Assaf Harofeh Medical Center, Zerifin, Israel

P690: Comparative efficacy of vedolizumab and adalimumab as second-line therapy in ulcerative colitis patients previously treated with infliximab

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Favale1, S. Onali*1, F. Caprioli2, D. Pugliese3, A. Armuzzi3, F. S. Macaluso4, A. Orlando4, A. Viola5, W. Fries5, G. Mocci6, F. Chicco7, P. Usai7, A. Rispo8, F. Castiglione8, E. Calabrese1, L. Biancone1, G. Monteleone1, M. C. Fantini1

1Università degli studi di Roma, Tor Vergata, Roma, Italy, 2Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Università degli studi di Milano, Milano, Italy, 3Fondazione Policlinico Universitario Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy, 4Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy, 5Università degli studi di Messina, Messina, Italy, 6Azienda Ospedaliera Brotzu, Cagliari, Italy, 7Università degli studi di Cagliari, Cagliari, Italy, 8Università Federico II di Napoli, Napoli, Italy

P691: Trends in diagnostic prevalence and treatment patterns of adult ulcerative colitis patients in the USA, 2007–2017

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Hunter*1, A. Naegeli1, Y. Dong1, C. Choong1, D. Stefani-Hunyady1

1Eli Lilly and Company, Indianapolis, USA

P692: Positive histological margins is a risk factor of recurrence after ileocaecal resection in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Riault*1, M. Diouf2, D. Chatelain2, J. p. Le Mouel1, J. Loreau1, J. Turpin1, C. Yzet1, F. Brazier1, C. Sabbagh2, J. l. Dupas1, E. Nguyen-Khac1, M. Fumery1

1Amiens University Hospital, Gastro-enterology, Amiens, France, 2Amiens University Hospital, Amiens, France

P693: Vedolizumab treatment for pouch inflammation

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Hirsch*1, H. Tulchinsky2, N. Maharshak1

1Tel Aviv Medical Center, Gastroenterology and liver diseases, Tel Aviv, Israel, 2Tel Aviv Medical Center, Department of Surgery, Tel Aviv, Israel